Dayvigo Generic Name & Formulations
Mechanism of Action
Dayvigo Dosage and Administration
Dayvigo Boxed Warnings
CNS depression. Daytime impairment (including impaired driving w. 10mg dose). Monitor for somnolence. Discontinue immediately if any complex sleep behaviors develop. Compromised respiratory function (eg, moderate to severe COPD, mild to severe obstructive sleep apnea). Suicidal ideation or behavior. Depression. Monitor for worsening insomnia or new cognitive/behavioral abnormalities. Reevaluate if unresponsive after 7–10 days of treatment. Severe renal or mild hepatic impairment: possible increased risk of somnolence. Severe hepatic impairment: not recommended. Drug or alcohol abusers. Elderly. Pregnancy. Nursing mothers.
The time to peak concentration (tmax) of lemborexant is ~1 to 3 hours. Lemborexant Cmax decreased by 23%, AUC0-inf increased by 18%, and tmax was delayed by 2 hours following administration of a high-fat and high-calorie meal (containing approximately 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively).
The volume of distribution of lemborexant is 1970 L. Plasma protein binding of lemborexant is ~88% in vitro and 94% in clinical samples.
Following administration of an oral dose, 57.4% of the dose was recovered in the feces and 29.1% in the urine (<1% as unchanged). The effective half-life for lemborexant 5 mg and 10 mg is 17 and 19 hours, respectively.
Dayvigo Adverse Reactions
Dayvigo Clinical Trials
Dayvigo Patient Counseling